Prophylactic pancreatic stent placement to prevent pancreatitis after ERCP
- PMID: 38219770
- DOI: 10.1016/S0140-6736(23)02719-8
Prophylactic pancreatic stent placement to prevent pancreatitis after ERCP
Conflict of interest statement
MLK reports financial relationships, unrelated to the topic of this Comment, as follows: serving as a consultant for Applied Clinical Intelligence (adjudication committee), Boston Scientific Corporation (tissue acquisition), Castle Biosciences (Barretts diagnostics), Dark Canyon Laboratories (colonoscopy preparation), Endiatx (steerable capsule), Olympus (scientific advisory panel), and Virgo Systems (artificial intelligence); and holding equity in the American Gastroenterological Association and Varia Ventures GI Opportunity Fund (venture capital), Dark Canyon Laboratories (colonoscopy preparation), Endiatx (steerable capsule), Endosound (endoscopic ultrasound device), Varia Ventures (venture capital), and Virgo Systems (artificial intelligence). PIK declares no competing interests.
Comment on
-
Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.Lancet. 2024 Feb 3;403(10425):450-458. doi: 10.1016/S0140-6736(23)02356-5. Epub 2024 Jan 11. Lancet. 2024. PMID: 38219767 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
